Drug Discovery 2017
Print Print
Presentation
Tue 3 October
4 October
[Schedule with Tracks only]
DAY 1ROOM 3HALL 1CHALL 1BRoom 11aExhibition Hall
DAY 2
DAY 1ROOM 3HALL 1CHALL 1BRoom 11aExhibition Hall
DAY 2
8:00 Registration & Coffee 8:00:
8:05: 8:05:
8:10: 8:10:
8:15: 8:15:
8:20: 8:20:
8:25: 8:25:
8:30: 8:30:
8:35: 8:35:
8:40: Introduction to Plenary Keynote
08:40 (5 mins)
 8:40:
8:45:
Plenary Keynote
Transforming R&D productivity; How can we better turn science into medicine
08:45 (45 mins)
Mene Pangalos, AstraZeneca  
 8:45:
8:50: 8:50:
8:55: 8:55:
9:00 9:00:
9:05: 9:05:
9:10: 9:10:
9:15: 9:15:
9:20: 9:20:
9:25: Essen Bioscience, now part of Sartorius
Cutting-edge cellular analysis techniques: cases studies in drug discovery?
 9:25:
9:30: Session Chair Introductions - Innovations in Assay Design, Development and Screening
09:30 (15 mins)
Florian Fuchs (Novartis)		 Session Chair Introductions - Drug Discovery in the 4th Dimension
09:30 (15 mins)
Jon Hutchinson (GSK) 		Session Chair Introductions - Advances in Imaging
09:30 (15 mins)
Prof Richard Bayliss (Leeds), Prof Neil Carragher (Edinburgh		 Welcome & Introduction - Workshop
09:30 (5 mins)
Peter Djali ( Intellicyt).		 9:30:
9:35: Bryan Miller (Sygnature Discovery) Use of Live-Cell Imaging Assays for Immuno-oncology in Integrated Drug Discovery Programmes
09:35 (20 mins)
 9:35:
9:40: 9:40:
9:45:
Innovations in Assay Design, Development and Screening
Chairs: Florian Fuchs, Novartis  
Biofabrication of Human Tissue Models
09:45 (45 mins)
Keynote Speaker: Petra Kluger, Fraunhofer Institute for Interfacial Engineering and Biotechnology co. Reutlingen University  
CROP-seq - Pooled CRISPR screens with single-cell transcriptome readout
10:30 (30 mins)
Paul Datlinger, CeMM Research Center for Molecular Medicine, Vienna  
Drug Discovery in the 4th Dimension
The value of binding kinetics to drug discovery
09:45 (45 mins)
Keynote Speaker: David Swinney, iRND3  
How to measure and interpret the “fourth” dimension
10:30 (30 mins)
Advances in Imaging
Chairs: Richard Bayliss, University of Leeds   Neil Carragher, University of Edinburgh  
Molecular Imaging of cancer in the future: Monitoring treatment response by imaging oncogenic rewiring and immune microenvironment changes, through combining whole body imaging with tissue / exosome-based approaches
09:45 (45 mins)
Keynote Speaker: Tony Ng, Kings College London and University College London  
Advances in Magnetic Resonance Imaging of cancer: translating from concept to clinical application
10:30 (30 mins)
Shonit Punwani, Centre for Medical Imaging-UCL  
Test
11:00 (15 mins)
Frederic Bassilana, Novartis Institutes for BioMedical Research (NIBR)  
 9:45:
9:50: 9:50:
9:55: Rachel Forfar (LifeArc) Developing an Assay Platform for Screening and Characterisation of Antibody Drug Conjugates
09:55 (20 mins)
 9:55:
10:00 10:00
10:05 10:05
10:10 10:10
10:15 Rosemary Burke (The Institute of Cancer Research) Use of IncuCyte® Live-Cell Analysis in Cancer Drug Discovery Programs
10:15 (20 mins)
 10:15
10:20 10:20
10:25 10:25
10:30 10:30
10:35 Del Trezise (Essen BioScience) What’s new with IncuCyte® and iQue Screener®?: Focus on Immunology & 3D spheroids
10:35 (20 mins)
 10:35
10:40 10:40
10:45 10:45
10:50 10:50
10:55 10:55
11:00 Coffee Break 11:00
11:05 11:05
11:10 11:10
11:15 11:15
11:20 11:20
11:25 11:25
11:30
Innovations in Assay Design, Development and Screening
A Microphysiological System Built For 3D Microtissue Spheroids
11:30 (30 mins)
Olivier Frey, InSphero AG  
Drug Discovery in the 4th Dimension
NanoBRET: An experimental approach to monitoring binding kinetics in cells
11:30 (30 mins)
Kelly Gatfield, GSK  
Advances in Imaging
Detecting early tumour responses to treatment using molecular imaging
11:30 (30 mins)
Kevin Brindle, University of Cambridge  
 11:30
11:35 11:35
11:40 11:40
11:45 11:45
11:50 11:50
11:55 11:55
12:00 Poster Spotlight - Poster 7 - Linda Gijzen, MIMETAS B.V
12:00 (15 mins)
High-Throughput Microfluidic Platform for Culture of 3D-Kidney Tissue Models 		Genedata AG
Genedata Screener scales systematic capture of kinetic and mechanistic information across the organization - Kevin Teburi Managing Director, Genedata Ltd. • R&D organizations increasingly rely on de...[More]
 Merck Life Science
Imaging Flow Cytometry for illuminating the complexities of drug effects. Dr Owen Hughes Amnis imaging flow cytometers are automated, high speed microscopes that numerically quantify cellular morphol...[More]
 12:00
12:05 Corning Life Sciences
A Novel Three Dimensional Immune Oncology Model for High Throughput Testing of Tumoricidal Capability - Kevin Jones : There has been increasing interest in utilizing immune cells for cancer treatmen...[More]
 BioTek Instruments
From physiologically 3D tumor invasion model to autophagy and neuroscience applications using Cytation 5 -Antoine Fouillet Cytation 5 is a multi-mode cell imager making it the most versatile instrume...[More]
 12:05
12:10 Promega UK Ltd
NanoBRET™ target engagement assays for determining compound affinity and residence time kinetics - Dr Craig Malcolm This snapshot talk will describe Promega’s NanoBRET™ Target Engagement Assay, which...[More]
 LGC - ATCC
ATCC advanced in-vitro models for drug discovery - Romuald Menth Ph.D. An overview of the advanced cellular models from ATCC including; primary diseased state cells, cell models developed using CRIS...[More]
 12:10
12:15
Innovations in Assay Design, Development and Screening
Encoded peptide libraries in drug discovery
12:15 (30 mins)
Christoph Dumelin, Novartis Pharma AG  
Drug Discovery in the 4th Dimension
Making use of molecular dynamics simulations in structure-based design of kinase drugs
12:15 (30 mins)
Yibing Shan, D E Shaw Research  
Advances in Imaging
Phenotypic screening of anti-cancer agents in 3D-cultured human tissues
12:15 (30 mins)
Bram Herpers, OcellO B.V.  
 12:15
12:20 12:20
12:25 12:25
12:30 12:30
12:35 12:35
12:40 12:40
12:45 Lunch (Exhibition Hall, Posters) SLAS Author Workshop: How to get your work published
12:45 (75 mins)
Rob Howes - AstraZeneca		 12:45
12:50 12:50
12:55 12:55
1:00 1:00:
1:05: 1:05:
1:10: 1:10:
1:15: 1:15:
1:20: 1:20:
1:25: 1:25:
1:30: 1:30:
1:35: 1:35:
1:40: 1:40:
1:45: 1:45:
1:50: 1:50:
1:55: 1:55:
2:00
Innovations in Assay Design, Development and Screening
Understanding mode of action using BRET and FRET cell based assays to investigate MALT1 proteolytic and scaffolding function
14:00 (30 mins)
Helena Peilot Sjögren, AstraZeneca  
Drug Discovery in the 4th Dimension
Optimizing Binding Kinetics in Medicinal Chemistry: facts or fantasy?
14:00 (30 mins)
Gerhard Mueller, Gotham Therapeutics  
Advances in Imaging
Multiparametric High-Content Cell Imaging and Image-Informatics: Advancing Phenotypic Drug Discovery
14:00 (30 mins)
Neil Carragher, University of Edinburgh  
 2:00:
2:05: 2:05:
2:10: 2:10:
2:15: 2:15:
2:20: 2:20:
2:25: 2:25:
2:30: Nexcelom from PerkinElmer
Get closer to the picture and data with image based cytometry for 2D and 3D screening assays - Dr Ravindra Chaudhari The Celigo® S Image Cytometer is a bench-top, micro-well plate based, whole well b...[More]
 Poster Spotlight - Poster 29 - Claire McWhirter, AstraZeneca
14:30 (15 mins)
Use of AssayQuant Fluorogenic Peptides to Determine the Mechanism of Compound Inhibition and Potency for a Range of Tyrosine and Serine/Threonine Kinases. bstract 		Poster Spotlight - Poster75 - Frank Craig
14:30 (15 mins)
Cyto-Mine® is the world’s first fully integrated instrument system for high-throughput single cell screening and dispensing, using microfluidic picodroplet technologies. By encapsulating single cells in picolitre volume water-in-oil droplets, Cyto-Mine® enables rapid detection of molecules (e.g. antibodies) secreted by individual cells, followed by selective cloning of single cells based on specific antibody production and titre. The system also allows label-free selection and deposition of single cells into well of 96- and 384-well MTPs - ensuring high fidelity monoclonality assurance (required for FDA-approval of all monoclonal antibodies). Data will be presented showing rapid, ultra-sensitive Ab detection, sorting and dispensing of antibody-secreting cells.		 2:30:
2:35: 2:35:
2:40: 2:40:
2:45: BMG LABTECH Ltd
The Need for Speed - Catherine Wark Recent advances in instrumentation performance at BMG LABTECH have provided the tools to complete kinetic assays in a High Throughput fashion. For HTRF applicatio...[More]
 Eurofins Discovery
Use of high-content imaging to evaluate oncology drugs and facilitate predictive genomic biomarker identification - Alastair J. King, Ph.D. The OncoPanel™ Cell-based Profiling Service is a fully auto...[More]
 2:45:
2:50: FUJIFILM Cellular Dynamics
Giorgia Salvagiotto. The clear need for more translational models in drug discovery has geared research efforts towards innovative technologies that could enable better prediction of the in vivo outc...[More]
 Sygnature Discovery
Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programmes. Marie Fisher Sygnature Discovery is the UK’s largest independent provider of integrated drug discover...[More]
 2:50:
2:55: Hamilton Sales & Service UK Ltd.
 Tecan UK Ltd
Tecans Spark Plate Reader and its Brightfield Imaging Capabilities - Alistair Robertson.
2:55:
3:00 Coffee Break 3:00:
3:05: 3:05:
3:10: 3:10:
3:15: 3:15:
3:20: 3:20:
3:25: 3:25:
3:30: 3:30:
3:35: 3:35:
3:40: 3:40:
3:45:
Innovations in Assay Design, Development and Screening
A platform for the generation and high throughput screening of cyclic peptide libraries
15:45 (30 mins)
Ali Tavassoli, University of Southampton  
Development of an HTS assay for modulation of enzyme function in tissue preparations
16:15 (30 mins)
Joanne Shearer, Charles River Laboratories  
Drug Discovery in the 4th Dimension
Deciphering GPCR-ligand interactions through structural and biophysical investigations
15:45 (30 mins)
Rob Cooke, Heptares Therapeutics  
Improving the Prediction of In vivo Drug Activity
16:15 (30 mins)
Peter Tonge, Stony Brook University  
Advances in Imaging
Cryo-EM as a tool in modern biomedical discovery
15:45 (30 mins)
Neil Ranson, University of Leeds  
Dynamic equilibrium of Aurora-A kinase activation loop revealed by single molecule spectroscopy
16:15 (30 mins)
Charlotte Dodson, Imperial College London  
 3:45:
3:50: 3:50:
3:55: 3:55:
4:00 4:00:
4:05: 4:05:
4:10: 4:10:
4:15: 4:15:
4:20: 4:20:
4:25: 4:25:
4:30: 4:30:
4:35: 4:35:
4:40: 4:40:
4:45: Poster Spotlight - Poster 22 - Gerrit Erdmann, NMI TT Pharmaservices
16:45 (10 mins)
Signal transduction profiling and resistance marker identification in primary ovarian cancer 		Poster Spotlight - Poster 72 - Anders Hanning, Episentum AB
16:45 (15 mins)
Label-Enhanced SPR for Improved Surface Plasmon Resonance Analysis of Small Molecules and Biomolecules 		Poster Spotlight - Poster 81 - Katherine Carr
16:45 (5 mins)
The Affimer biotherapeutic protein scaffold is based on human Stefin A and is a small ~14 kDa protein about 1/10th the size of an antibody. It has no post translational modifications making it easier to manufacture. Two surface loops in Stefin A have been engineered into the scaffold backbone to create large Affimer phage libraries (1x1011). This library has been used to screen for Affimer binders to human Programmed death-ligand 1 (PDL1) that compete for the PD-1 epitope. One of the single digit nM affinity PD-1 antagonists (AVA04-261) is presented here, co-crystallised with a domain of PDL1. This is the first non-antibody protein scaffold structure bound to PDL1.
PDL1 plays an important role in the modulation of the immune system and has been clinically validated as a target for a number of human cancers with monoclonal antibodies (mAbs). Crystal structures elucidating how antibodies, antibody fragments - and small molecules bind and inhibit PD-1 are available. The Affimer scaffold offers an alternative to mAbs as therapeutics due to their flexibility in formatting options and easy of manufacture. Here we describe an Affimer protein that specifically binds to human PDL1 and competes with PD-1/CD80 binding. The crystal structure of the Affimer protein bound to human PDL1, solved here to ~ 2.5 A resolution shows how the two engineered loops interact directly with the flat PDL1 binding surface.We present the protein production and complex formation.
 4:45:
4:50: 4:50:
4:55: IntelliCyt Corporation
IntelliCyt Assays: from Discovery to Production - Dr Peter Djali. The iQue platform is well known as an enabling platform for high throughput suspension cell assays. In this snapshot we’ll explore th...[More]
 4:55:
5:00 Drinks reception & Posters in The Exhibition Hall 5:00:
5:05: 5:05:
5:10: 5:10:
5:15: 5:15:
5:20: 5:20:
5:25: 5:25:
5:30: 5:30:
5:35: 5:35:
5:40: 5:40:
5:45: 5:45:
5:50: 5:50:
5:55: 5:55:
6:00 6:00:
6:05: 6:05:
6:10: 6:10:
6:15: 6:15:
6:20: 6:20:
6:25: 6:25:
6:30: 6:30:
6:35: 6:35:
6:40: 6:40:
6:45: 6:45:
6:50: 6:50:
6:55: 6:55:
7:00 7:00: